Table 2 PEGylated filgrastim-induced aortitis among breast cancer patients treated with neoadjuvant or adjuvant chemotherapy.
Case 1 | Case 2 | Case 3 | Case 4 | Case 5 | Case 6 | |
|---|---|---|---|---|---|---|
Baseline characteristics | ||||||
Age | 45 years | 66 years | 49 years | 50 years | 59 years | 53 years |
Gender | Female | Female | Female | Female | Female | Female |
Race | Asian | Asian | Asian | Asian | Asian | Asian |
Comorbidity | None | Hypertension Hypothyroidism | Hypertension | None | None | None |
Chemotherapy indication | Neoadjuvant | Neoadjuvant | Adjuvant | Adjuvant | Adjuvant | Adjuvant |
Chemotherapy regimen | Docetaxel Carboplatin | Docetaxel Carboplatin | Docetaxel Cyclophosphamide | Docetaxel Cyclophosphamide | Docetaxel Carboplatin Trastuzumab Hertuzumab | Docetaxel Cyclophosphamide |
G-CSF type at the onset of aortitis | Pegfilgrastim Filgrastim(Recurrence) | Pegfilgrastim | Pegfilgrastim | Pegfilgrastim | Pegfilgrastim | Pegfilgrastim |
Frequency of pegfilgrastim before aortitis | 5 | 3 | 1 | 1 | 1 | 4 |
Clinical manifestations | ||||||
Symptoms | Fever Myalgia Chilling Epigastric discomfort | Fever Chilling Myalgia Nausea | Fever Chest discomfort Dyspepsia Myalgia | Fever Chilling Myalgia | Fever Myalgia Chilling | Fever Chilling Myalgia Headache |
Physical examination | Abdominal tenderness | Abdominal tenderness | Unremarkable | Unremarkable | Unremarkable | Unremarkable |
Time to onset | (1st) 12 days (2nd) 10 days | 13 days | 15 days | 12 days | 17 days | 14 days |
Extent of disease | Aortic arch Abdominal aorta | Aortic arch Left CCA Right innominate artery Thoracic aorta Abdominal aorta | Aortic arch Left CCA | Aortic arch Right innominate artery Left SCA Left CCA | Aortic arch Left CCA Right innominate artery Thoracic aorta Abdominal aorta | Aortic arch Left CCA |
Laboratory findings | ||||||
WBC count, × 103/μL | 7.46 (Neutrophil-dominant) | 19.76 (Neutrophil-dominant) | 12.33 (Neutrophil-dominant) | 38.29 (Neutrophil-dominant) | 16.91 (Neutrophil-dominant) | 11.25 (Neutrophil-dominant) |
ESR, mm/h | 53 | 118 | 119 | 69 | 120 | 64 |
CRP, mg/dL | 23.11 | 26.63 | 21.76 | 29.58 | 32.86 | 10.85 |
Procalcitonin, ng/mL | 0.04 | 0.26 | 0.18 | 0.05 | 0.28 | 0.04 |
Blood culture | Negative | Negative | Negative | Negative | Negative | Negative |
Infection serologya | Negative | Negative | Negative | Negative | Negative | Negative |
Rheumatologic markers | RF/FANA/ANCA (–/–/–) | RF/FANA/ANCA (–/–/–) | RF/FANA/ANCA (–/–/–) | RF/FANA/ANCA (–/–/–) | RF/FANA/ANCA (–/–/–) | No data |
Immunoglobulin (IgG4) | No data | No data | Normal | Normal | Negative | No data |
